Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Convertible Debt (2016 - 2018)

Viking Therapeutics (VKTX) has disclosed Convertible Debt for 5 consecutive years, with $1.5 million as the latest value for Q1 2018.

  • For Q1 2018, Convertible Debt fell 59.6% year-over-year to $1.5 million; the TTM value through Mar 2018 reached $1.5 million, down 59.6%, while the annual FY2017 figure was $1.5 million, 0.0% changed from the prior year.
  • Convertible Debt hit $1.5 million in Q1 2018 for Viking Therapeutics, roughly flat from $1.5 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $3.7 million in Q1 2017 and bottomed at $1.3 million in Q4 2014.
  • Average Convertible Debt over 5 years is $1.8 million, with a median of $1.5 million recorded in 2016.
  • Year-over-year, Convertible Debt skyrocketed 119.57% in 2016 and then crashed 59.6% in 2018.
  • Viking Therapeutics' Convertible Debt stood at $1.3 million in 2014, then soared by 70.2% to $2.2 million in 2015, then tumbled by 30.28% to $1.5 million in 2016, then changed by 0.0% to $1.5 million in 2017, then changed by 0.0% to $1.5 million in 2018.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $1.5 million, $1.5 million, and $1.5 million for Q1 2018, Q4 2017, and Q3 2017 respectively.